Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Reiser M et al. – The acute hepatic porphyrias can cause life–threatening attacks of neurovisceral symptoms that mimic other acute medical conditions. Variegate porphyria caused by mutations in the protoporphyrinogen oxidase (PPOX) gene is a latent disorder characterized by exacerbations induced by fasting, alcohol consumption or certain drugs. The authors describe the case of a 46–year–old female patient presenting with a first episode of symptomatic porphyria after 10 d of sibutramine treatment for weight loss. Genetic analysis showed a heterozygous R168H hot spot mutation in the PPOX gene. A putative effect of sibutramine on the hepatic haem biosynthetic pathway and reduced food intake have likely caused this exacerbation of a porphyria attack. Although this may be the first case report of this kind, the risk of acute porphyria should be considered in patients using pharmacotherapy for obesity.

Related Articles

The value of drugs for obesity in the management of cardiovascular risk factors
Sang Thrombose Vaisseaux, 11/04/09    Relevance Score: 77%

Intentional weight loss and risk of lymphohematopoietic cancers
Cancer Causes and Control, 10/28/09    Relevance Score: 71%

Interpreting weight losses from lifestyle modification trials: using categorical data
International Journal of Obesity, 10/19/09    Relevance Score: 71%

Racial/Ethnic Differences in Weight Perceptions and Weight Control Behaviors Among Adolescent Females
Youth & Society, 11/11/09    Relevance Score: 69%

Interindividual variations in resting metabolic rate during weight loss in obese postmenopausal women: A pilot study
Metabolism-Clinical and Experimental, 11/03/09    Relevance Score: 69%

Today in Adverse Drug Reactions...keeping you current

Pregabalin, celecoxib, and their combination for treatment of chronic low-back pain
Journal of Orthopaedics and Traumatology, 11/24/09

Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies
British Journal of Clinical Pharmacology, 11/24/09

Appraising the post-marketing safety of medicines: A description of national and international pharmacovigilance with a focus on medicines used in chronic pain
Current Anaesthesia and Critical Care, 11/24/09

Today in Other Drugs...keeping you current

Glibenclamide-related excess in total and cardiovascular mortality risks: Data from large Ukrainian observational cohort study
Diabetes Research and Clinical Practice, 11/24/09

Pregabalin, celecoxib, and their combination for treatment of chronic low-back pain
Journal of Orthopaedics and Traumatology, 11/24/09

DPP-4 Inhibitors in Clinical Practice
Postgraduate Medicine, 11/24/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address